[HTML][HTML] Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review
Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise
in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is …
in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is …
EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4–positive solid tumors, including metastatic urothelial carcinoma
J Rosenberg, SS Sridhar, J Zhang, D Smith… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV),
a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting …
a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting …
[HTML][HTML] Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
J Hamad, H McCloskey, MI Milowsky, T Royce… - International braz j …, 2020 - SciELO Brasil
Background Standard management of muscle-invasive bladder cancer involves radical
cystectomy with pelvic lymph node dissection. However, patients may be ineligible for …
cystectomy with pelvic lymph node dissection. However, patients may be ineligible for …
[HTML][HTML] Identification and validation of an individualized prognostic signature of bladder cancer based on seven immune related genes
H Qiu, X Hu, C He, B Yu, Y Li, J Li - Frontiers in genetics, 2020 - frontiersin.org
Background There has been no report of prognostic signature based on immune-related
genes (IRGs). This study aimed to develop an IRG-based prognostic signature that could …
genes (IRGs). This study aimed to develop an IRG-based prognostic signature that could …
[HTML][HTML] EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients
G Zhu, L Pei, Y Li, X Gou - Aging (albany NY), 2020 - ncbi.nlm.nih.gov
Bladder cancer is a leading cause of morbidity and mortality worldwide. Currently,
immunotherapy has become a worthwhile therapy for bladder cancer. Tumor mutation …
immunotherapy has become a worthwhile therapy for bladder cancer. Tumor mutation …
Androgen receptor‐regulated circ FNTA activates KRAS signaling to promote bladder cancer invasion
The androgen receptor (AR) has been linked to bladder cancer (BC a) progression, but if
this involves circular RNA s (circ RNA s) remains unclear. Here, we find that AR alters the …
this involves circular RNA s (circ RNA s) remains unclear. Here, we find that AR alters the …
Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma
V Margulis, M Puligandla, EJ Trabulsi… - The Journal of …, 2020 - auajournals.org
Purpose: Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial
carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated …
carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated …
[HTML][HTML] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
S Takahashi, M Uemura, T Kimura, Y Kawasaki… - Investigational new …, 2020 - Springer
Locally advanced or metastatic urothelial cancer is an aggressive form of cancer with high
recurrence rates and low survival. Nectin-4 is a cell adhesion molecule commonly …
recurrence rates and low survival. Nectin-4 is a cell adhesion molecule commonly …
[HTML][HTML] Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes
H Li, Q Zhang, L Shuman, M Kaag, JD Raman… - Scientific reports, 2020 - nature.com
Although advanced bladder cancer overall has a poor prognosis, a subset of patients
demonstrate durable response to immune checkpoint inhibitors. Evidence shows that the …
demonstrate durable response to immune checkpoint inhibitors. Evidence shows that the …
Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: results from multiple cohorts, including TCGA
Purpose: Studies indicate that molecular subtypes in muscle invasive bladder cancer predict
the clinical outcome. We evaluated whether subtyping by a simplified method and …
the clinical outcome. We evaluated whether subtyping by a simplified method and …